DUSP4 drives BRAF V600E-mutant colorectal cancer progression through TRIM27-mediated PTEN degradation and modulates tumor immune microenvironment

BACKGROUND: BRAF V600E-mutant colorectal cancer (CRC) has aggressive behavior and limited therapeutic options. We investigated whether dual-specificity phosphatase 4 (DUSP4) contributes to this phenotype and defined its molecular mechanism. METHODS: DepMap and GEO data were integrated to nominate BRAF V600E-selective candidates. DUSP4 expression was validated in 30 paired tumors/normal tissues and an independent cohort (n = 326). Gain/loss-of-function studies were performed in HT29/RKO cells and xenografts. IP-MS, co‑IP, immunofluorescence, cycloheximide chase, inhibitor assays, and ubiquitination assays defined the mechanism. CD8+ T cells were analyzed by flow cytometry and chemokines by ELISA. RESULTS: DUSP4 was preferentially expressed in BRAF V600E‑mutant CRC and associated with nodal (P = 0.005) and distant metastasis (P = 0.019), and shorter overall survival. High DUSP4 independently predicted mortality [HR=2.102, 95%CI 1.395-3.165, P < 0.001]. Overexpression promoted proliferation, migration, and xenograft growth; knockdown produced opposite effects. Mechanistically, DUSP4 reduced PTEN protein stability and activated PI3K-AKT. DUSP4 recruited E3 ligase TRIM27, promoting K48‑linked polyubiquitination and proteasomal degradation of PTEN. TRIM27 manipulation partially rescued DUSP4‑dependent phenotypes. In vitro, DUSP4-overexpressing CRC cells impaired CD8+ T cell function, as evidenced by decreased expression of IFN-γ, GZMB, and CD107a. DUSP4 overexpression was associated with downregulated CXCL9/16, IFN-γ, TNF-α, and IL-2, and upregulated IL-10, effects partially reversed by PTEN overexpression. CONCLUSIONS: DUSP4 is preferentially expressed in BRAF V600E-mutant CRC and independently predicts poor prognosis. It promotes tumor progression via a novel TRIM27-PTEN-PI3K-AKT axis, and modulates the immune microenvironment by impairing CD8+ T cell function. DUSP4 may serve as a candidate prognostic biomarker and warrants further investigation as a potential therapeutic target.

Authors

Institutions

Publication Details

Journal
Translational Oncology
Published
2026-11-16
DOI
https://doi.org/10.1016/j.tranon.2026.103119
Primary Topic
Protein Tyrosine Phosphatases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

DUSP4 drives BRAF V600E-mutant colorectal cancer progression through TRIM27-mediated PTEN degradation and modulates tumor immune microenvironment

Ziqi Zhang, Qingyang Feng, Kaiyu Wang, Zhiyuan Zhang et al.
1 links
Translational Oncology
Protein Tyrosine Phosphatases
article

DUSP4 drives BRAF V600E-mutant colorectal cancer progression through TRIM27-mediated PTEN degradation and modulates tumor immune microenvironment

Ziqi Zhang, Qingyang Feng, Kaiyu Wang, Zhiyuan Zhang, Donghao Xu, Qihao Pan, Peng Zheng, Yifan Ding, Hengyue Zhang, Jianmin Xu
article en

Abstract

BACKGROUND: BRAF V600E-mutant colorectal cancer (CRC) has aggressive behavior and limited therapeutic options. We investigated whether dual-specificity phosphatase 4 (DUSP4) contributes to this phenotype and defined its molecular mechanism. METHODS: DepMap and GEO data were integrated to nominate BRAF V600E-selective candidates. DUSP4 expression was validated in 30 paired tumors/normal tissues and an independent cohort (n = 326). Gain/loss-of-function studies were performed in HT29/RKO cells and xenografts. IP-MS, co‑IP, immunofluorescence, cycloheximide chase, inhibitor assays, and ubiquitination assays defined the mechanism. CD8+ T cells were analyzed by flow cytometry and chemokines by ELISA. RESULTS: DUSP4 was preferentially expressed in BRAF V600E‑mutant CRC and associated with nodal (P = 0.005) and distant metastasis (P = 0.019), and shorter overall survival. High DUSP4 independently predicted mortality [HR=2.102, 95%CI 1.395-3.165, P < 0.001]. Overexpression promoted proliferation, migration, and xenograft growth; knockdown produced opposite effects. Mechanistically, DUSP4 reduced PTEN protein stability and activated PI3K-AKT. DUSP4 recruited E3 ligase TRIM27, promoting K48‑linked polyubiquitination and proteasomal degradation of PTEN. TRIM27 manipulation partially rescued DUSP4‑dependent phenotypes. In vitro, DUSP4-overexpressing CRC cells impaired CD8+ T cell function, as evidenced by decreased expression of IFN-γ, GZMB, and CD107a. DUSP4 overexpression was associated with downregulated CXCL9/16, IFN-γ, TNF-α, and IL-2, and upregulated IL-10, effects partially reversed by PTEN overexpression. CONCLUSIONS: DUSP4 is preferentially expressed in BRAF V600E-mutant CRC and independently predicts poor prognosis. It promotes tumor progression via a novel TRIM27-PTEN-PI3K-AKT axis, and modulates the immune microenvironment by impairing CD8+ T cell function. DUSP4 may serve as a candidate prognostic biomarker and warrants further investigation as a potential therapeutic target.

Translational OncologyVol. 75
Fudan University (CN), Shanghai Xuhui Central Hospital (CN), Zhongshan Hospital (CN)
Good health and well-being
Protein Tyrosine Phosphatases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon